2 results
Approved WMOCompleted
Cohort 1 (HER2-positive/amplified MBC): MCLA-128 + trastuzumab ± vinorelbine Primary objective:• Evaluate efficacy of MCLA-128 combined with trastuzumab ± vinorelbine in terms of clinical benefit rate (CBR) at 24 weeks based on RECIST 1.1 (per…
Approved WMOCompleted
Our primary objectives are to decode **signatures** of activity from the electrode that might prelude or accompany an OCD attack, by analyzing its activity in an experimental setting and in real-life situations, and to correlate symptom changes with…